Risk factor
Significant default risk
Profitability factor
Very low or no dividends
About
Polus BioPharm Inc. operates as a biopharmaceutical company in South Korea. Its products in pipeline includes PDP808, an insulin glargine biosimilar for treating diabetes; PDP805, a somatropin biosimilar used for treating growth hormone deficiency; PDP807, a ranibizumab biosimilar for the treatment of macular degeneration; and PDP815, an insulin lispro biosimilar used for treating diabetes. The company was formerly known as Amnis Co., Ltd. and changed its name to Polus BioPharm Inc. in December 2017. Polus BioPharm Inc. was founded in 1972 and is based in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Buy
Sell